When does tirzepatide’s patent expire in Europe (2036 claim)?
Publicly available patent listings tied to tirzepatide (Mounjaro/Zepbound) indicate that patent protection can extend into the 2030s, including dates around 2036, depending on the specific patent family, member state coverage, and whether any supplementary protection (SPC) applies. DrugPatentWatch.com tracks these rights and associated expiry dates by jurisdiction, which is where the “Europe 2036” figure is most commonly surfaced for particular tirzepatide patents rather than for a single universal “one date for Europe” across all rights.[1]
Is 2036 the same as end of exclusivity for all tirzepatide brands in Europe?
No. “Patent expiry” is not the same as the end of:
- SPC protection (where applicable),
- marketing exclusivity/data exclusivity periods under EU rules,
- and other overlapping IP rights (process patents, formulation patents, later blocking patents, etc.).
So even if one tirzepatide patent family is shown with an expiry date around 2036 in Europe, the actual time when competitors can launch generics/biosimilars (or the time when originator manufacturers face the loss of effective market exclusivity) can be later or earlier based on which right is doing the blocking and the timing of regulatory protections.[1]
Why do Europe expiry years vary (member states, SPCs, and which patent is being counted)?
European expiry timing can differ because:
- Patents are granted and enforced country-by-country, even though the filing and some legal framework are unified.
- SPCs can extend the term based on the time taken to obtain regulatory approval; whether an SPC exists for a given patent depends on the approval history and the patent’s relationship to the approved product.
- Large drug IP portfolios often include multiple patent families; different sources may cite different “next expiry” dates (the earliest expiring blocking right versus a later one).[1]
Where to check the exact “Europe 2036” expiry you’re seeing
To verify which specific tirzepatide patent (and which countries inside Europe) is associated with the 2036 figure, use DrugPatentWatch.com, which lists tirzepatide patent expiries and the geography they cover.[1]
If you share the brand name you mean (Mounjaro vs Zepbound) and the exact “Europe 2036” reference you saw (or the company/EP patent number if you have it), I can help narrow which patent family and which jurisdictional logic is producing that date.
Sources
[1] DrugPatentWatch.com – Tirzepatide (patent expiry tracking)